Regenxbio Inc (NASDAQ:RGNX) SVP Patrick J. Christmas sold 15,000 shares of the company’s stock in a transaction on Wednesday, November 7th. The shares were sold at an average price of $72.06, for a total value of $1,080,900.00. Following the completion of the transaction, the senior vice president now directly owns 2,669 shares in the company, valued at $192,328.14. The sale was disclosed in a filing with the SEC, which is available through this link.
Shares of RGNX stock traded up $0.44 on Monday, hitting $60.35. 486,500 shares of the company’s stock were exchanged, compared to its average volume of 531,420. Regenxbio Inc has a 12 month low of $23.25 and a 12 month high of $85.10. The company has a market cap of $2.15 billion, a P/E ratio of -24.63, a P/E/G ratio of 8.84 and a beta of -0.52.
Regenxbio (NASDAQ:RGNX) last posted its earnings results on Wednesday, November 7th. The biotechnology company reported ($0.56) EPS for the quarter, beating the consensus estimate of ($0.86) by $0.30. The firm had revenue of $5.31 million during the quarter. Regenxbio had a return on equity of 22.52% and a net margin of 44.30%. On average, analysts anticipate that Regenxbio Inc will post 2.23 EPS for the current year.
RGNX has been the subject of a number of recent analyst reports. Leerink Swann initiated coverage on Regenxbio in a research report on Tuesday, November 27th. They set an “underperform” rating and a $42.00 target price for the company. Zacks Investment Research downgraded Regenxbio from a “strong-buy” rating to a “hold” rating and set a $70.00 target price for the company. in a research report on Wednesday, November 14th. TheStreet downgraded Regenxbio from a “c” rating to a “d+” rating in a research report on Friday, August 10th. Bank of America upped their target price on Regenxbio from $76.00 to $84.00 and gave the company a “neutral” rating in a research report on Thursday, November 8th. Finally, BidaskClub upgraded Regenxbio from a “hold” rating to a “buy” rating in a research report on Saturday, November 3rd. One analyst has rated the stock with a sell rating, four have given a hold rating and five have issued a buy rating to the stock. Regenxbio has a consensus rating of “Hold” and an average target price of $77.81.
COPYRIGHT VIOLATION WARNING: This article was first reported by Baseball Daily News and is owned by of Baseball Daily News. If you are accessing this article on another site, it was stolen and reposted in violation of US & international copyright & trademark law. The legal version of this article can be viewed at https://www.baseballdailydigest.com/news/2018/12/03/patrick-j-christmas-sells-15000-shares-of-regenxbio-inc-rgnx-stock.html.
REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform.
Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter.